FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2756552974> ?p ?o ?g. }

• W2756552974 endingPage "80" @default.
• W2756552974 startingPage "69" @default.
• W2756552974 abstract "•High amplification levels of MDM2 (>38 copies) and CDK4 (>30 copies) correlate with both decreased disease free survival (P = .0168 and 0.0169 respectively) and disease specific survival (P = .0082 and 0.0140 respectively). Amplified MDM2 and CDK4 displayed a synergistic effect so that each additional copy of one enhances the effect on prognosis of each additional copy of the other for decreased DFS (P = .0227, 0.1% hazard). •Higher amplification levels of JUN (>16 copies) significantly correlated with decreased disease free survival (P = .0217). •Overall, our study showed that gene amplification levels in DDLS can be useful for predicting patient outcome and cutoff points were determined. Dedifferentiated liposarcoma (DDLS) is characterized at the molecular level by amplification of genes within 12q13-15 including MDM2 and CDK4. However, other than FNCLCC grade, prognostic markers are limited. We aim to identify molecular prognostic markers for DDLS to help risk stratify patients. To this end, we studied 49 cases of DDLS in our institutional archives and performed cytogenomic microarray analysis on 47 cases. Gene copy numbers for 12 loci were evaluated and correlated with outcome data retrieved from our institutional electronic medical records. Using cut point analysis and comparison of Kaplan-Meier survival curves by log rank tests, high amplification levels of MDM2 (>38 copies) and CDK4 (>30 copies) correlated with decreased disease free survival (DFS) (P = .0168 and 0.0169 respectively) and disease specific survival (DSS) (P = .0082 and 0.0140 respectively). Additionally, MDM2 and CDK4 showed evidence of a synergistic effect so that each additional copy of one enhances the effect on prognosis of each additional copy of the other for decreased DFS (P = .0227, 0.1% hazard). High amplification of JUN (>16 copies) also correlated with decreased DFS (P = .0217), but not DSS. The presence of copy number alteration at 3q29 correlated with decreased DSS (P = .0192). The presence of >10 mitoses per 10 high power fields and FNCLCC grade 3 also correlated with decreased DFS (P = .0310 and 0.0254 respectively). MDM2 and CDK4 gene amplification levels, along with JUN amplification and copy alterations at 3q29, can be utilized for predicting outcome in patients with DDLS. Dedifferentiated liposarcoma (DDLS) is characterized at the molecular level by amplification of genes within 12q13-15 including MDM2 and CDK4. However, other than FNCLCC grade, prognostic markers are limited. We aim to identify molecular prognostic markers for DDLS to help risk stratify patients. To this end, we studied 49 cases of DDLS in our institutional archives and performed cytogenomic microarray analysis on 47 cases. Gene copy numbers for 12 loci were evaluated and correlated with outcome data retrieved from our institutional electronic medical records. Using cut point analysis and comparison of Kaplan-Meier survival curves by log rank tests, high amplification levels of MDM2 (>38 copies) and CDK4 (>30 copies) correlated with decreased disease free survival (DFS) (P = .0168 and 0.0169 respectively) and disease specific survival (DSS) (P = .0082 and 0.0140 respectively). Additionally, MDM2 and CDK4 showed evidence of a synergistic effect so that each additional copy of one enhances the effect on prognosis of each additional copy of the other for decreased DFS (P = .0227, 0.1% hazard). High amplification of JUN (>16 copies) also correlated with decreased DFS (P = .0217), but not DSS. The presence of copy number alteration at 3q29 correlated with decreased DSS (P = .0192). The presence of >10 mitoses per 10 high power fields and FNCLCC grade 3 also correlated with decreased DFS (P = .0310 and 0.0254 respectively). MDM2 and CDK4 gene amplification levels, along with JUN amplification and copy alterations at 3q29, can be utilized for predicting outcome in patients with DDLS." @default.
• W2756552974 created "2017-10-06" @default.
• W2756552974 creator A5018174947 @default.
• W2756552974 creator A5031905122 @default.
• W2756552974 creator A5042287198 @default.
• W2756552974 creator A5042724179 @default.
• W2756552974 creator A5048669688 @default.
• W2756552974 creator A5071249969 @default.
• W2756552974 creator A5073836752 @default.
• W2756552974 creator A5082243346 @default.
• W2756552974 creator A5090194993 @default.
• W2756552974 date "2017-12-01" @default.
• W2756552974 modified "2023-10-14" @default.
• W2756552974 title "High amplification levels of MDM2 and CDK4 correlate with poor outcome in patients with dedifferentiated liposarcoma: A cytogenomic microarray analysis of 47 cases" @default.
• W2756552974 cites W1258808631 @default.
• W2756552974 cites W1944656442 @default.
• W2756552974 cites W1980858272 @default.
• W2756552974 cites W1985761271 @default.
• W2756552974 cites W1991144688 @default.
• W2756552974 cites W1994487360 @default.
• W2756552974 cites W1999662788 @default.
• W2756552974 cites W2005066824 @default.
• W2756552974 cites W2011653982 @default.
• W2756552974 cites W2014583828 @default.
• W2756552974 cites W2017117404 @default.
• W2756552974 cites W2020097472 @default.
• W2756552974 cites W2026121915 @default.
• W2756552974 cites W2027632544 @default.
• W2756552974 cites W2034292565 @default.
• W2756552974 cites W2038491907 @default.
• W2756552974 cites W2042194227 @default.
• W2756552974 cites W2056530510 @default.
• W2756552974 cites W2058373115 @default.
• W2756552974 cites W2060084956 @default.
• W2756552974 cites W2067535881 @default.
• W2756552974 cites W2073533521 @default.
• W2756552974 cites W2113799786 @default.
• W2756552974 cites W2123359711 @default.
• W2756552974 cites W2125972676 @default.
• W2756552974 cites W2126650918 @default.
• W2756552974 cites W2128560398 @default.
• W2756552974 cites W2131853603 @default.
• W2756552974 cites W2140495144 @default.
• W2756552974 cites W2152235903 @default.
• W2756552974 cites W2157803976 @default.
• W2756552974 cites W2551242059 @default.
• W2756552974 cites W2565546335 @default.
• W2756552974 cites W2612879655 @default.
• W2756552974 cites W81266651 @default.
• W2756552974 doi "https://doi.org/10.1016/j.cancergen.2017.09.005" @default.
• W2756552974 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29153098" @default.
• W2756552974 hasPublicationYear "2017" @default.
• W2756552974 type Work @default.
• W2756552974 sameAs 2756552974 @default.
• W2756552974 citedByCount "42" @default.
• W2756552974 countsByYear W27565529742018 @default.
• W2756552974 countsByYear W27565529742019 @default.
• W2756552974 countsByYear W27565529742020 @default.
• W2756552974 countsByYear W27565529742021 @default.
• W2756552974 countsByYear W27565529742022 @default.
• W2756552974 countsByYear W27565529742023 @default.
• W2756552974 crossrefType "journal-article" @default.
• W2756552974 hasAuthorship W2756552974A5018174947 @default.
• W2756552974 hasAuthorship W2756552974A5031905122 @default.
• W2756552974 hasAuthorship W2756552974A5042287198 @default.
• W2756552974 hasAuthorship W2756552974A5042724179 @default.
• W2756552974 hasAuthorship W2756552974A5048669688 @default.
• W2756552974 hasAuthorship W2756552974A5071249969 @default.
• W2756552974 hasAuthorship W2756552974A5073836752 @default.
• W2756552974 hasAuthorship W2756552974A5082243346 @default.
• W2756552974 hasAuthorship W2756552974A5090194993 @default.
• W2756552974 hasConcept C104317684 @default.
• W2756552974 hasConcept C10515644 @default.
• W2756552974 hasConcept C126322002 @default.
• W2756552974 hasConcept C143998085 @default.
• W2756552974 hasConcept C150194340 @default.
• W2756552974 hasConcept C193270364 @default.
• W2756552974 hasConcept C204232928 @default.
• W2756552974 hasConcept C207103383 @default.
• W2756552974 hasConcept C2776192174 @default.
• W2756552974 hasConcept C2779134260 @default.
• W2756552974 hasConcept C2780265364 @default.
• W2756552974 hasConcept C3019894029 @default.
• W2756552974 hasConcept C44249647 @default.
• W2756552974 hasConcept C502942594 @default.
• W2756552974 hasConcept C54355233 @default.
• W2756552974 hasConcept C71924100 @default.
• W2756552974 hasConcept C7602840 @default.
• W2756552974 hasConcept C8415881 @default.
• W2756552974 hasConcept C86803240 @default.
• W2756552974 hasConceptScore W2756552974C104317684 @default.
• W2756552974 hasConceptScore W2756552974C10515644 @default.
• W2756552974 hasConceptScore W2756552974C126322002 @default.
• W2756552974 hasConceptScore W2756552974C143998085 @default.
• W2756552974 hasConceptScore W2756552974C150194340 @default.
• W2756552974 hasConceptScore W2756552974C193270364 @default.
• W2756552974 hasConceptScore W2756552974C204232928 @default.
• W2756552974 hasConceptScore W2756552974C207103383 @default.

• next